BR9809932A - Métodos para tratamento de distúrbios trombóticos - Google Patents

Métodos para tratamento de distúrbios trombóticos

Info

Publication number
BR9809932A
BR9809932A BR9809932-9A BR9809932A BR9809932A BR 9809932 A BR9809932 A BR 9809932A BR 9809932 A BR9809932 A BR 9809932A BR 9809932 A BR9809932 A BR 9809932A
Authority
BR
Brazil
Prior art keywords
thrombotic disorders
methods
combination therapy
limited
treating
Prior art date
Application number
BR9809932-9A
Other languages
English (en)
Inventor
Brian William Grinnell
Joseph Anthony Jakubowski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9809932A publication Critical patent/BR9809932A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Patente de Invenção: <B>"MéTODOS PARA TRATAMENTO DE DISTúRBIOS TROMBóTICOS''<D>. A presente invenção apresenta um método para o tratamento de pacientes com vários distúrbios trombóticos, incluindo, mas não limitados a derrame, trombose venosa, infarto do miocárdio, angina instável, fechamento abrupto após angioplastia ou colocação de sonda, e trombose como resultado de cirurgia vascular periférica. O dito tratamento é uma terapia de combinação com aPC humana e agentes antiplaquetários, incluindo, mas não limitados a, aspirina (ASA), clopidogrel, ReoPro<32> (abciximab), dipiridamol, ticlopidina e antagonistas do receptor de IIb/IIIa. A sinergia resulta na capacidade de reduzir as dosagens dos agentes usados na terapia de combinação.
BR9809932-9A 1997-06-05 1998-06-01 Métodos para tratamento de distúrbios trombóticos BR9809932A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4862897P 1997-06-05 1997-06-05
PCT/US1998/011071 WO1998055142A1 (en) 1997-06-05 1998-06-01 Methods for treating thrombotic disorders

Publications (1)

Publication Number Publication Date
BR9809932A true BR9809932A (pt) 2000-08-01

Family

ID=21955575

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809932-9A BR9809932A (pt) 1997-06-05 1998-06-01 Métodos para tratamento de distúrbios trombóticos

Country Status (23)

Country Link
US (1) US6071514A (pt)
EP (1) EP0882453B1 (pt)
JP (1) JP2002502421A (pt)
KR (1) KR20010013413A (pt)
CN (2) CN1265598A (pt)
AT (1) ATE286404T1 (pt)
AU (1) AU741983B2 (pt)
BR (1) BR9809932A (pt)
CA (1) CA2293429A1 (pt)
DE (1) DE69828462T2 (pt)
DK (1) DK0882453T3 (pt)
EA (1) EA199901112A1 (pt)
ES (1) ES2235291T3 (pt)
HU (1) HUP0003964A2 (pt)
ID (1) ID23908A (pt)
NO (1) NO995776L (pt)
PL (1) PL337223A1 (pt)
PT (1) PT882453E (pt)
SI (1) SI0882453T1 (pt)
TR (1) TR199903020T2 (pt)
TW (1) TWI228042B (pt)
WO (1) WO1998055142A1 (pt)
ZA (1) ZA984698B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062828A1 (en) * 1996-04-30 2000-10-26 Medtronic, Inc. Autologous fibrin sealant and method for making the same
JP2000509307A (ja) * 1996-04-30 2000-07-25 メドトロニック，インコーポレイテッド 自己由来フィブリン密封材の製造方法
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
EP1255556B1 (en) * 2000-02-04 2011-04-06 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030056244A1 (en) * 2000-05-02 2003-03-20 Ning Huang Feed additive compositions and methods
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US6942880B1 (en) * 2001-04-09 2005-09-13 Medtronic, Inc. Autologous platelet gel having beneficial geometric shapes and methods of making the same
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
EP1453529A4 (en) * 2001-09-19 2007-09-26 Oklahoma Med Res Found TREATMENT OF SEPSIS WITH TAFI
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
EP1448205B1 (en) * 2001-10-05 2011-03-23 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
WO2004062551A2 (en) 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
CA2647497C (en) * 2006-04-04 2016-01-12 Cogentus Pharmaceuticals, Inc. Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2007127841A2 (en) * 2006-04-26 2007-11-08 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof
MX2008014828A (es) * 2006-05-22 2009-02-06 Combinatorx Inc Metodos y composiciones para el tratamiento de enfermedades o condiciones asociadas con niveles incrementados de proteina c-reactiva, interleucina-6 o interferon-gamma.
NZ581362A (en) 2007-04-27 2011-07-29 Cydex Pharmaceuticals Inc Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
EP2203174A4 (en) * 2007-09-19 2010-09-29 Combinatorx Inc THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
MX2010006724A (es) * 2007-12-17 2010-09-07 Combinatorx Inc Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.
DE102007063234A1 (de) * 2007-12-31 2009-07-02 Nowak, Attila, Dipl.-Ing. Schnellere Speicherorganisation
US20100280594A1 (en) * 2009-05-01 2010-11-04 Medi-Solve, Llc Antithrombotic Neurovascular Device Containing a Glycoprotein IIB/IIIA Receptor Inhibitor for The Treatment of Brain Aneurysms and/or Acute Ischemic Stroke, and Methods Related Thereto
ES2769949T3 (es) 2009-05-13 2020-06-29 Cydex Pharmaceuticals Inc Composiciones farmacéuticas que comprenden prasugrel y derivados de ciclodextrina y métodos de preparación y uso de las mismas
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals

Also Published As

Publication number Publication date
US6071514A (en) 2000-06-06
EP0882453A3 (en) 2001-04-04
EP0882453B1 (en) 2005-01-05
DK0882453T3 (da) 2005-05-09
ATE286404T1 (de) 2005-01-15
DE69828462D1 (de) 2005-02-10
WO1998055142A1 (en) 1998-12-10
TWI228042B (en) 2005-02-21
ES2235291T3 (es) 2005-07-01
JP2002502421A (ja) 2002-01-22
NO995776L (no) 2000-01-26
SI0882453T1 (en) 2005-06-30
TR199903020T2 (xx) 2000-08-21
AU7710098A (en) 1998-12-21
CA2293429A1 (en) 1998-12-10
AU741983B2 (en) 2001-12-13
PL337223A1 (en) 2000-08-14
ID23908A (id) 2000-05-25
CN1347734A (zh) 2002-05-08
KR20010013413A (ko) 2001-02-26
DE69828462T2 (de) 2005-12-15
EP0882453A2 (en) 1998-12-09
PT882453E (pt) 2005-04-29
ZA984698B (en) 2000-02-01
NO995776D0 (no) 1999-11-25
HUP0003964A2 (en) 2001-03-28
CN1265598A (zh) 2000-09-06
EA199901112A1 (ru) 2000-06-26

Similar Documents

Publication Publication Date Title
BR9809932A (pt) Métodos para tratamento de distúrbios trombóticos
AR058359A1 (es) Combinaciones
ATE538801T1 (de) Therapeutische zusammensetzungen mit mindestens einem pyrrolobenzodiazepin-derivat und fludarabin
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
ATE331522T1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
BRPI0414331A (pt) método de destruição de bactéria numa área de tratamento do paciente e composição antimicrobiana de terapia fotodinámica
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
DE60238921D1 (de) Verbesserte handgehaltene lasereinrichtung zur hautbehandlung
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
NO920946L (no) Oral antikoagulant/blodplateinhibitor i lavdoseformulering
PT1140181E (pt) Terapia de combinacao de radiacao e um inibidor de cox-2 para o tratamento da neoplasia
BR9911049A (pt) Terapia combinada para tratamento de depressão resistente
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
BR0010669A (pt) Método para o tratamento de fibrose usando um antagonista da subunidade alfa-4 da integrina
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
BRPI0410844A (pt) fator de crescimento de fibroblasto de codificação de plasmìdeo para o tratamento de defeitos angiogênicos associados com hipercolesterolemia ou diabetes
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
DE19983519T1 (de) Vorrichtung zur Wärmebehandlung von Körpergewebe
ATE245448T1 (de) Zellwachstumshemmende zusammensetzungen die kalzium-zufluss-blocker enthalten
BR0315374A (pt) Compostos orgânicos

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART 36 DA LPI (LEI 9.279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.